A later study corroborated this observation, and demonstrated that the accumulation of ROS in mutant p53 cancer cells can be exploited as a therapeutic strategy, by pharmacologic depletion of glutathione (GSH), which specifically targets mutant-p53-expressing cells [80]. This evidence concerns the gene TP53 and cancer.